Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Shots:Philochem and RayzeBio (BMS) entered into a development and commercialization agreement under which Philochem granted RayzeBio exclusive worldwide rights to develop, manufacture, and commercialize its radiopharmaceutical agent OncoACP3 for prostate cancer Under the agreement, Philochem will receive $350M up front and is eligible for up to $1B in development, regulatory, and commercial milestones, plus…

ByPrince Giri3 days ago

News

Nuevocor Reports the US FDA’s IND Clearance of NVC-001 for LMNA DCM

Shots:The US FDA has approved the IND application of NVC-001 to treat LMNA-related dilated cardiomyopathy (LMNA DCM), enabling a P-I/II trial to start in early 2026Preclinical studies showed that NVC-001 significantly improved survival and cardiac function. They planned a P-I/II trial, a 52-week, open-label, multicenter ascending-dose study to assess the safety, tolerability, and…

ByPrince Giri3 days ago

News

OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Shots:OS Therapies joined hands with EVERSANA to commercialize OST-HER2 in the US for the treatment of pediatric lung metastatic osteosarcomaThis partnership leverages EVERSANA’s integrated commercialization platform, including market access, medical affairs, field deployment, patient services, and stakeholder engagement enabling OS Therapies to bring OST-HER2 to market rapidly and cost-effectivelyOS Therapies recently secured…

ByPrince Giri3 days ago

News

Regeneron Highlights Dupixent (dupilumab) Data From P-IV (DISCOVER) Study at RAD’25

Shots :Regeneron highlighted the data at RAD’25 from the P-IV (DISCOVER) study evaluating Dupixent in pts (N=120) with atopic dermatitis with skin of color that received Dupixent as monotx. Q2W based on weight after loading dose: 200mg for 30-60kg pts & 300mg for ≥60kg ptsDupixent achieved a ≥75% improvement in overall disease severity…

ByPrince Giri4 days ago

News

The US FDA Approves Merck’s ENFLONSIA for RSV Prevention in Infants

Shots :Merck’s ENFLONSIA has been approved by the US FDA to prevent RSV lower respiratory tract disease in newborns and infants entering their first RSV season, offering protection for up to 5mos. with a single 105mg dose, regardless of weightThe approval was supported by the P-IIb/III (CLEVER) study of ENFLONSIA that demonstrated reduced…

ByPrince Giri4 days ago

News

Daiichi Sankyo Reports First Patient Dosing in P-III (DESTINY-Endometrial01) Study Evaluating ENHERTU

Shots :Daiichi reported the first patient dosing in a P-III (DESTINY-Endometrial01) study evaluating ENHERTU (trastuzumab deruxtecan) + rilvegostomig or pembrolizumab vs Pt. chemotx. (carboplatin and paclitaxel) + pembrolizumab as 1L therapy, in HER2-expressing (IHC 3+/2+), pMMR advanced or recurrent endometrial cancer ptsThe study is assessing the efficacy and safety of ENHERTU (5.4 mg/kg)…

ByPrince Giri4 days ago

INSIGHTS+

Know Your Investor: Deep Track Capital (June’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…

ByPrince GiriJune 5, 2025

TOP 20

Top 20 Diagnostics Companies of 2025

Top 20 Diagnostics Companies of 2025 Shots: Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%.…

ByPrince GiriMay 29, 2025

TOP 20

Top 20 Medical Device Companies of 2025

Shots: Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcareIn 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…

ByPrince GiriMay 22, 2025

News

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Shots:RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platformsThis collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platformsRecent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…

ByPrince GiriMay 21, 2025

Prince Giri

Philochem and RayzeBio Enter Into a Development and Commercialization Deal of ~$1.35B

Nuevocor Reports the US FDA’s IND Clearance of NVC-001 for LMNA DCM

OS Therapies & EVERSANA Partner to Commercialize OST-HER2 in the US for Pediatric Osteosarcoma

Regeneron Highlights Dupixent (dupilumab) Data From P-IV (DISCOVER) Study at RAD’25

The US FDA Approves Merck’s ENFLONSIA for RSV Prevention in Infants

Daiichi Sankyo Reports First Patient Dosing in P-III (DESTINY-Endometrial01) Study Evaluating ENHERTU

Know Your Investor: Deep Track Capital (June’25 Edition)

Top 20 Diagnostics Companies of 2025

Top 20 Medical Device Companies of 2025

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Contact US

OUR INFORMATION

FOLLW US

Prince Giri

FOLLW US

Sign Up to Our Newsletter